In a revolutionary move in biopharma, Profluent, an AI-first protein design company, has developed the world’s first AI-generated and open-source gene editor. The model named OpenCRISPR-1, leverages the power of μεγάλα γλωσσικά μοντέλα (LLMs) and CRISPR technology. With this new technology, Profluent aims to democratize gene editing, offering customizable solutions designed from scratch with AI.
Διαβάστε επίσης: Τεχνητή Νοημοσύνη και Γενετική: Ανακάλυψη Σπάνιας Αλληλουχίας DNA
The Fusion of AI and CRISPR
Profluent pioneers the fusion of AI and CRISPR technology, bridging the gap between τεχνητή νοημοσύνη and genetic engineering. By training its AI on massive databases of protein sequences, Profluent generates novel CRISPR-like proteins and instructional RNA molecules, expanding the repertoire of gene editing tools available to scientists.
OpenCRISPR Initiative
Under the OpenCRISPR initiative, Profluent releases OpenCRISPR-1, an AI-created gene editor freely available to the public. Unlike traditional gene editing methods, OpenCRISPR-1 boasts over 400 mutations, offering enhanced precision and reduced off-target effects. Profluent’s CEO, Ali Madani, emphasizes the initiative’s goal of democratizing gene editing to accelerate therapeutic innovation.
Διαβάστε επίσης: Η τεχνητή νοημοσύνη κατασκευάζει ασύλληπτα αντισώματα: Η νέα προσέγγιση του LabGenius στην ιατρική μηχανική
Democratizing Gene Editing
Profluent’s commitment to democratizing gene editing aims to make CRISPR medicines more accessible and versatile. By leveraging AI to design gene editing systems from scratch, Profluent enables researchers to explore new therapeutic avenues previously unattainable with conventional methods. The company’s Chief Business Officer, Hilary Eaton, highlights the potential of OpenCRISPR to revolutionize genetic therapies for a wide range of diseases.
Διαβάστε επίσης: Αποκωδικοποίηση του σχεδιαγράμματος της ζωής: AI's Geneformer
Μελλοντικές επιπτώσεις
The introduction of OpenCRISPR-1 marks a significant milestone in the field of gene editing. It paves the way for unprecedented advancements in precision medicine. With the potential to tailor treatments to individual patients and address previously incurable diseases, Profluent’s AI-driven approach heralds a new era of therapeutic innovation. Peter Cameron, Vice President of Gene Editing at Profluent, emphasizes the collaborative nature of the initiative, inviting feedback and collaboration from the gene editing community.
Λόγο μας
Profluent’s OpenCRISPR-1 represents a paradigm shift in gene editing technology, combining the ingenuity of AI with the precision of CRISPR. By democratizing access to AI-generated gene editors, Profluent empowers researchers to explore novel therapeutic interventions. It helps to further accelerate the development of life-saving treatments. As we embark on this transformative journey towards personalized medicine, collaboration, and innovation will be key drivers of success in harnessing the full potential of gene editing technology.
Ακολουθήστε μας στο ειδήσεις Google για να μείνετε ενημερωμένοι με τις τελευταίες καινοτομίες στον κόσμο της τεχνητής νοημοσύνης, της επιστήμης δεδομένων και GenAI.
- SEO Powered Content & PR Distribution. Ενισχύστε σήμερα.
- PlatoData.Network Vertical Generative Ai. Ενδυναμώστε τον εαυτό σας. Πρόσβαση εδώ.
- PlatoAiStream. Web3 Intelligence. Ενισχύθηκε η γνώση. Πρόσβαση εδώ.
- PlatoESG. Ανθρακας, Cleantech, Ενέργεια, Περιβάλλον, Ηλιακός, Διαχείριση των αποβλήτων. Πρόσβαση εδώ.
- PlatoHealth. Ευφυΐα βιοτεχνολογίας και κλινικών δοκιμών. Πρόσβαση εδώ.
- πηγή: https://www.analyticsvidhya.com/blog/2024/04/profluent-opencrispr-revolutionizing-gene-editing-with-ai/